What question did this study set out to answer?

The aim is to assess real-world outcomes of bortezomib-based regimens in newly diagnosed multiple myeloma patients.

April 19, 2026HaematologicaOpen Access

P25 | Real-World Outcomes in Newly Diagnosed Multiple Myeloma: Evidence Supporting Bortezomib–lenalidomide–dexamethasone as a Preferred Regimen Without Anti-Cd38 Antibodies

View Full Paper

Ask AI

Bookmark

Authors

AJA. JungovaCharles University MSM. StorkUniversity Hospital Brno ISI SpickaCharles University

Discussion

Member takes

Implication

This retrospective study evaluates the effectiveness of bortezomib-based regimens in newly diagnosed multiple myeloma, suggesting optimal management strategies.

Key Points

The aim is to assess real-world outcomes of bortezomib-based regimens in newly diagnosed multiple myeloma patients.
Retrospective analysis of 2281 patients across four regimens: VMP, CVD, VTD, VRD.
Data sourced from the national RMG database.
Outcomes assessed included treatment exposure, response rates, progression-free survival, and overall survival using standard statistical methods.
Subgroup analyses conducted for elderly patients and those with various health complications.
VRD had the highest overall response rate at 90.4% and the longest progression-free survival (27.7 months) and overall survival (43.0 months).
Patients over 75 years and those with renal impairment showed similar outcomes across regimens.
Toxicity-driven discontinuation was most common in VRD, highlighting the need for careful management of side effects.

Cite This Study

Jungova et al. (2026) studied this question.

synapsesocial.com/papers/69e4702d010ef96374d8d62e https://doi.org/10.3324/haematol.2026.s2.14036

View Full Paper

Ask AI

Bookmark

Implication

This retrospective study evaluates the effectiveness of bortezomib-based regimens in newly diagnosed multiple myeloma, suggesting optimal management strategies.

P25 | Real-World Outcomes in Newly Diagnosed Multiple Myeloma: Evidence Supporting Bortezomib–lenalidomide–dexamethasone as a Preferred Regimen Without Anti-Cd38 Antibodies

Discussion

Member takes

Implication

Key Points

Cite This Study

P25 | Real-World Outcomes in Newly Diagnosed Multiple Myeloma: Evidence Supporting Bortezomib–lenalidomide–dexamethasone as a Preferred Regimen Without Anti-Cd38 Antibodies

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider